Randomized clinical trials provide the most reliable evidence to guide the management of stroke and threatened stroke and reflect the interests of the stroke research community. The spectrum of phase III randomized clinical trials in stroke has not been previously characterized.
Methods
Phase III stroke randomized clinical trials published between 2012 and 2014 were identified by search of the Cochrane Central Register of Controlled Trials supplemented by recent publications known to the co-authors.
Results
Thirty-four randomized clinical trials were included involving 85 770 participants: 20 acute stroke randomized clinical trials (32 590 patients), 11 stroke prevention randomized clinical trials (28 964 patients), and three randomized clinical trials in which stroke was a major component of a composite primary outcome involving nonstroke patients (24 216 patients). Twenty-two (65%) trials were international, and eight (24%) were industry sponsored. Drugs were tested in 21 (62%) randomized clinical trials, with devices (n = 9), surgery (n = 3), and diet (n = 1) in the remainder. Thirteen (38%) randomized clinical trials were stopped early: seven for futility, three for efficacy, two for harm, and one for budget/administrative reasons. Overall, the results of seven (21%) randomized clinical trials were positive, five (15%) equivocal, 18 (53%) negative, and four (12%) inconclusive. Considering positive and definitively negative randomized clinical trials testing currently used interventions, 11 (32%) randomized clinical trials have direct implications for clinical management.
Conclusions
The diversity of interventions, high-quality, and worldwide origins of recently published phase III randomized clinical trials reflects a vibrant international stroke research community. The current generation of stroke randomized clinical trials provides important guidance for stroke prevention and acute stroke care.
GladstoneDJSpringMDorianP for the EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med2014; 370: 2467–77.
2.
SannaTDienerH-CPassmanRS for the CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med2014; 370: 2478–86.
3.
NogueiraRGLutsepHLGuptaR for the TREVO2 trialists. Trevo vs. Merci retrivers for thrombectoly revascularization of large vessel occlusions in acute ischaemic stroke (TREVO 2): A randomised trial. Lancet2012; 380: 1231–40.
4.
SaverJLJahanRLevyE for the SWIFT Trialists. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. Lancet2012; 380: 1241–9.
5.
CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): A multicenter randomised controlled trial. Lancet2013; 382: 516–24.
6.
LeesKRBornsteinNDienerH-C. Results of Membrane-activated Chelator Stroke Intervention Randomized Trial of DP-b99 in acute ischemic stroke. Stroke2013; 44: 580–4.
7.
JadadARMooreRACarrollD. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Control Clin Trials1996; 17: 1–12.
8.
HeissW-DBraininMBornsteinNMTuomilehtoJHongZ, for the Cerebolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebolysin in patients with acute ischemic stroke in Asia. Results of a double-blind, placebo-controlled, randomized trial. Stroke2012; 43: 630–6.
9.
IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]: A randomised controlled trial. Lancet2012; 379: 2352–63.
10.
DavalosAAlvarez-SabinJCastilloJ for the International Citicholine Trial on acUte Stroke (ICTUS) investigators. Citicholine in the treatment of acute ischemic stroke. An international, randomised, multicenter, placebo-controlled study (ICTUS trial). Lancet2012; 380: 349–57.
11.
MeesDorhout SMAlgraAVandertopWP. Magnesium for aneurismal subarachnoid haemorrhage (MASH-2): A randomised placebo-controlled trial. Lancet2012; 380: 44–9.
12.
ZinkstokSMRoosYB, on behalf of the ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: A randomised controlled trial. Lancet2012; 380: 731–7.
13.
BroderickJPPaleschYYDemchukAM for the Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med2013; 368: 893–903.
14.
CicconeAValvassoriLNichelattiM for the SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med2013; 368: 904–13.
15.
AndersonCSHeeleyEHuangY for the INTERACT2 Investigators. Rapid blood pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med2013; 368: 2355–65.
16.
WangYWangYZhaoX for the CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med2013; 369: 11–9.
17.
MendelowADGregsonBARowanEN. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): A randomised trial. Lancet2013; 382: 397–408.
18.
GinsbergMDPaleschYYHillMD for the ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose albumin treatment for acute ischemic stroke (ALIAS) part 2: A randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol2013; 12: 1049–58.
19.
HeJZhangYXuT for the CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: The CATIS randomized clinical trial. JAMA2014; 311: 479–89.
20.
JuttlerEUnterbergAWoitzikJ for the DESTINY II Investigators. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med2014; 370: 1091–100.
21.
ChamorroAAmaroSCastellanosM for the URICO-ICTUS Investigators. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): A randomised, double-blind phase 2b/3 trial. Lancet Neurol2014; 13: 453–60.
22.
KirkpatrickPJTurnerCLSmithCHutchinsonPJMurrayGD, for the STASH Collaborators. Simvastatin in aneurismal subarachnoid haemorrhage (STASH): A multicentre randomised phase 3 trial. Lancet Neurol2014; 13: 666–75.
23.
HackeWShellingerPDAlbersGW for the NEST 3 Committees and Investigators. Transcranial laser therapy in acute stroke therapy. Stroke2014; 45: 3187–93.
24.
ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): A partial-factorial randomised controlled trial. Lancet2015; 385: 617–28. doi: 10.1016/S0140-6736(14)61121-1; [published online ahead of print October 22, 2014].
25.
BerkhemerOAFransenPSSBeumerD for the MR CLEAN Investigators. A randomized trial of intraarterial therapy for acute ischemic stroke. N Engl J Med2015; 372: 11–20.
26.
FurlanAJReismanMMassaroJ for the CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med2012; 366: 991–9.
27.
SPS3 Investigators, BenaventeORHartRG. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med2012; 367: 817–25.
28.
MiaoZJiangLWuH. Randomized controlled trial of symptomatic middle cerebral artery stenosis. Endovascular versus medical therapy in a Chinese population. Stroke2012; 43: 3284–90.
29.
CarrollJDSaverJLThalerDE for the RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med2013; 368: 1092–100.
30.
MeierBKalesanBMattleHP for the PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med2013; 368: 1083–91.
31.
SPS3 Study Group, BenaventeORCoffeyCS. Blood pressure targets in patients with recent lacunar stroke: The SPS3 randomised trial. Lancet2013; 382: 507–15.
32.
GiuglianoRPRuffCTBraunwaldE for the ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med2013; 369: 2093–104.
33.
CaoY-JZhangXWangW-H. Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention: Results from a multicenter, randomized, parallel-group and controlled clinical trial. Chin Med J2013; 126: 4060–5.
34.
MohrJPParidesMKStapfC for the international ARUBA investigators. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): A multicenter, non-blinded, randomized trial. Lancet2014; 383: 614–21.
35.
AmarencoPDavisSJonesEF. The Aortic Arch Related Cerebral Hazard Trial Investigators. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke2014; 45: 1248–57.
36.
Di BiaseLBurkhardtJDSantangeliP. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation for atrial fibrillation with different anticoagulation management. Results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circ2014; 129: 2638–44.
37.
HommaSThompsonJLPullicinoPM. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med2012; 366: 1859–69.
38.
EstruchRRosESalas-SalvadoJ for the PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med2013; 368: 1279–90.
39.
IkedaYShimadaKTeramotoT. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors. A randomized clinical trial. JAMA2014; 312: 2510–20.
40.
Editors. China's medical research integrity questioned. Lancet2015; 385: 1365.
